| 辅 | 导 对 | 象 | 浙江正雅齿科股份有限公司 | | --- | --- | --- | --- | | 成立日 | | 期 | 2010-12-28 | | 注 册 | 资 | 本 | 36,000 万元 法定代表人 姚峻峰 | | 注 册 | 地 | 址 | 浙江省嘉兴市南湖区大桥镇兴业路 999号 | | 控股股东及 持 股 比 例 | | | 公司创始人姚峻峰直接持有发行人 20.91%股权,并通过诺敦医疗间接 | | | | | 持有公司 9.07%的股份,同时通过天津雅善管理咨询合伙企业(有限 | | | | | 合伙)间接持有公司 3.49%的股份,通过天津雅亿管理咨询合伙企业 | | | | | (有限合伙)间接持有公司 2.57%股权,通过天津雅而管理咨询合伙 | | | | | 企业(有限合伙)间接持有公司 1.30%股权,通过天津雅偲管理咨询 | | | | | 合伙企业(有限合伙)间接持有公司 1.24%股权,通过天津雅吾管理 | | | | | 咨询合伙企业(有限合伙)间接持有公司 0.99%股权,合计持有公司 | | | | | 39.57%的股份,为公司的控股股东、实 ...

牙齿这门生意，挺神奇。 一边是动辄几万元的隐形牙套，被贴上"精致消费升级"的标签；另一边却是价格战、需求放缓、监管收 紧，让整个赛道迅速降温。就在这种反差背景下，一家行业第三的国产隐形正畸企业再次启动IPO。近 日，据证监会披露，正雅齿科在浙江证监局完成IPO辅导备案。如果这是家普通企业，消息则会淹没在 每日数十条的备案新闻里，但它的特别之处就在于是国内隐形正畸市场的老三，仅次于国际巨头隐适美 和已上市的"牙套第一股"时代天使。 2003年，姚峻峰从英国赫尔大学MBA毕业。回国后，他没进投行，也没去外企，而是盯上了父亲所在 的医疗器械行业，创办正雅齿科。 事实上，这不是正雅第一次闯关IPO。2023年5月，正雅齿科就曾启动辅导备案，当时的辅导券商是中 金公司和国海证券，后来不了了之。此番卷土重来，辅导团队直接从"中金系"换成了"建投系"。要知 道，在投行圈这种临门一脚换保荐人的行为，通常意味着公司已经彻底抛弃了那种虚无缥缈的溢价幻 象，转而追求务实的过会确定性。 一 中金退出，建投接盘。 正雅齿科早在2023年5月就曾由"中金公司+国海证券"的组合保荐进行辅导，中金公司作为国内投行圈 的"贵族"，向来对项目要 ...

时代天使在德国的代理律师事务所Arnold Ruess代理律师Dr. Arno Riße表示："时代天使尊重并将遵守杜 塞尔多夫统一专利法院的裁定，但与此同时，我们将积极举证，证明暂停Live Now功能中特定模块的 判定是不合理的。时代天使高度重视知识产权，并始终谨慎确保不侵犯任何有效专利权。" 多年来，时代天使始终专注于隐形正畸领域创新解决方案的研发。公司拥有多项前沿的解决方案和产 品，包括：屡获奖项的angelButton天使扣、angelHook天使钩、A6前导下颌解决方案(已迎来十周年)、 angel KiD时代天使儿童解决方案以及IRS智能根骨系统。时代天使致力于为市场带来公平、健康的竞争 环境，让医生与患者共同受益。 智通财经APP获悉，时代天使科技有限公司(06699，下称"时代天使")表示，德国杜塞尔多夫统一专利法 院(Unified Patent Court of Düsseldorf)下达临时禁令，要求公司暂停使用自动更新方案功能("live now")中 的特定模块，这对使用时代天使隐形矫治产品的医生和患者影响甚微。该临时禁令仅适用于部分欧洲国 家，不包括西班牙、瑞士、英国及爱尔兰。公 ...

Investment Rating - The report indicates a positive investment outlook for the invisible orthodontics industry in China, projecting a compound annual growth rate (CAGR) of 13.9% from 2024 to 2030, with the market size expected to grow from 145 billion yuan in 2024 to 316 billion yuan by 2030 [8][9]. Core Insights - The invisible orthodontics market in China is characterized by a large patient population suffering from malocclusion, with a higher prevalence of complex cases compared to Western countries. The market is currently dominated by two major players, Angelalign and Invisalign, while local brands are emerging [5][6]. - The industry is experiencing rapid growth driven by technological advancements, increased consumer awareness, and a shift towards personalized treatment options. The competition is intensifying, but the overall market is expected to maintain a high growth trajectory [5][6][9]. Market Background - The invisible orthodontics industry in China has evolved over the past 20 years, transitioning from technology introduction to local innovation. Key milestones include the establishment of the first 3D printing production line for invisible aligners in 2007 and the introduction of regulatory frameworks to standardize the market [6][7]. - The demand for invisible orthodontics is significantly increasing due to rising aesthetic standards and the preference for less visible treatment options among consumers [5][8]. Market Status - The market size for invisible orthodontics in China is projected to reach 145 billion yuan in 2024, with a CAGR of 13.9% expected until 2030. The demand is driven by a high prevalence of malocclusion and the advantages of invisible aligners over traditional braces [8][9]. - The supply side is seeing advancements in materials technology, particularly in the development of heat-pressed film materials that enhance the performance of aligners [10]. Market Competition - The competitive landscape is marked by a "dual oligopoly" structure, with Angelalign and Invisalign leading the market. These companies leverage continuous technological innovation and extensive clinical data to build competitive advantages [16][17]. - The report identifies ten recommended brands in the market, highlighting their unique strengths and market positioning, such as Angelalign's extensive clinical database and Invisalign's patented technology [18][19][20]. Development Trends - The report outlines several key trends shaping the future of the invisible orthodontics industry, including enhanced control capabilities, increased predictability through AI and big data, reduced chairside time due to smart manufacturing, and expanded application flexibility through digital integration [31][32][33][34].

Core Viewpoint - The company reported strong financial performance for H1 2025, with significant growth in both revenue and net profit, driven by international expansion and improved domestic operations [1][2]. Financial Performance - The company achieved revenue of $161 million in H1 2025, representing a 33% increase year-over-year [1]. - Net profit attributable to shareholders reached $15 million, up 363% compared to the previous year [1]. - The number of cases handled was 225,800, reflecting a 47.7% increase [1]. International Expansion - The company saw a substantial increase in overseas cases, totaling 117,200, which is a 103.5% increase, and now accounts for 51.9% of total cases [1]. - Overseas revenue reached $72 million, marking a 123% increase, with its share of total revenue rising to 44% [1]. - The gross margin for the company was 61.2%, an increase of 2.96 percentage points, while the net profit margin for the overseas segment improved significantly, narrowing losses by 44.5 percentage points [1]. Domestic Operations - Domestic cases increased to 109,000, a 14% rise, with revenue of $90 million, a slight increase of 0.7% [1]. - The net profit from domestic operations was $17 million, up 52%, with a net profit margin of 19.2%, an increase of 6.5 percentage points [1][2]. Cost Management - The improvement in domestic net profit margin was attributed to the increased allocation of fixed costs from overseas operations and effective cost control measures [2]. - The overall gross margin for H1 2025 was 62.4%, remaining stable year-over-year, with a net profit margin of 9.1%, up 6.5 percentage points [2]. - The sales expense ratio, management expense ratio, and R&D expense ratio were 33.3%, 13.8%, and 7.9%, respectively, showing year-over-year decreases of 6.4, 4.5, and 0.7 percentage points [2]. Future Outlook - The company slightly adjusted its profit forecasts for 2025-2027, predicting net profits of $8.6 million, $15 million, and $27.8 million, respectively [2]. - The company is positioned as a leading player in the invisible orthodontics market, with strong brand and product capabilities, focusing on grassroots market penetration domestically and accelerating breakthroughs in overseas markets [2].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of HKD 103.5 per share, indicating a potential upside from the current price of HKD 69.10 [2][5][14]. Core Insights - The company's revenue and profit for the first half of 2025 exceeded market expectations, driven by stabilization in domestic operations and rapid growth in overseas markets [3][10]. - In 1H25, the company achieved revenue of USD 160 million, representing a 33.1% increase year-over-year, with domestic revenue at USD 89.68 million (+0.6%) and overseas revenue at USD 71.67 million (+123.1%) [3][10][11]. - The share of overseas revenue reached 44.4%, up 17.9 percentage points, highlighting its importance as a key revenue source [3][10]. - The number of clear-aligner cases completed in 1H25 was 226,000, a 47.7% increase, with domestic cases growing by 14.0% and overseas cases surging by 103.5% [11][12]. Financial Performance - The gross margin for 1H25 was stable at 62.4%, while adjusted net profit increased by 84.8% to USD 19.47 million, resulting in a net margin of 12.1% [4][13]. - The company plans to implement aggressive market strategies in the second half of 2025 to maintain market share and continue its overseas expansion [5][14]. - Revenue forecasts for 2025 and 2026 have been raised to USD 340 million and USD 420 million, respectively, reflecting stronger-than-expected overseas growth [5][14]. Valuation Metrics - The report projects adjusted net profits of USD 26.75 million for 2025 and USD 32.80 million for 2026, with corresponding P/E ratios of 85x and 70x [5][14]. - The company is positioned as a leader in the clear-aligner market in China, with its overseas growth trajectory being increasingly validated [5][14].

Investment Rating - The report indicates a positive outlook for the invisible orthodontics industry, projecting a compound annual growth rate (CAGR) of 13.9% from 2024 to 2030, with market size expected to grow from 145 billion to 316 billion yuan [16][17]. Core Insights - The invisible orthodontics market in China is characterized by a large patient population, with over 1 billion individuals suffering from malocclusion, and a significantly higher prevalence of complex cases (Class II/III) compared to Western countries [4][20]. - The industry is currently dominated by two major players, Angelalign and Invisalign, which have established a "dual oligopoly" market structure, leading to intense competition and innovation [6][35]. - The report highlights the increasing demand for invisible orthodontics driven by rising consumer awareness of aesthetics and comfort, as well as advancements in technology such as AI design and 3D printing [17][38]. Summary by Sections Industry Overview - Malocclusion is defined as a dental condition resulting from abnormal jaw relationships, affecting oral health and function, necessitating orthodontic treatment [3][7]. - The prevalence of malocclusion in China is notably high, with complex cases reaching 45-50%, significantly above the 20-40% range seen in Europe and America [4][20]. Market Size - The market size for invisible orthodontics in China is projected to increase from 100 billion yuan in 2019 to 145 billion yuan in 2024, and further to 316 billion yuan by 2030 [16][17]. - The demand for invisible orthodontics is expected to rise due to improved consumer aesthetics awareness and the effectiveness of invisible aligners compared to traditional methods [17]. Supply Chain Analysis - The supply chain consists of upstream suppliers of orthodontic materials, midstream service providers, and downstream dental institutions, with a notable trend towards digital integration and efficiency [5][26]. - The core material for invisible aligners has transitioned from imported monopolies to domestic production, stabilizing the market with key players like Angelalign and Invisalign [5][29]. Competitive Landscape - The competitive landscape is marked by a "dual oligopoly" led by Angelalign and Invisalign, with both companies leveraging continuous technological advancements and clinical data to maintain their market positions [6][35]. - The report notes that the introduction of centralized procurement in 2022 has led to significant price reductions, enhancing affordability and market penetration, especially in lower-tier cities [22][23]. Technological Advancements - Innovations in materials, such as the development of PETG and TPU for aligners, have improved treatment outcomes and patient comfort [29][38]. - The integration of AI and 3D printing technologies is expected to further enhance the precision and efficiency of orthodontic treatments, creating opportunities for new entrants in the market [38].

Summary of the Conference Call for Times Angel Company Overview - **Company**: Times Angel - **Industry**: Orthodontics and dental technology Key Points and Arguments Financial Performance - **Revenue Structure**: In the first half of the year, Times Angel reported revenue of $89.68 million from the Chinese market and $71.67 million from international markets [2][4] - **Case Growth**: The number of cases in the Chinese market grew by 14% to 109,000, while international cases surged by 103.5% to 117,000 [2] - **Operating Profit**: Operating profit in China increased by 52% to $17.19 million, while losses in international markets narrowed to $5.43 million [2][5] - **Cash Flow**: Operating cash flow increased by 194.4% to $17.54 million [2] Market Strategy - **Pricing Strategy**: The company expanded its case numbers in China through strategic price reductions, while international gross margins improved by 3 percentage points to 61.2% [2] - **Product Innovation**: New products launched include the A10 Angel Expander and the headgear-style muscle stimulator, along with digital tools like the i also platform and "Angel Xiao Zhi" [2][6] - **Supply Chain Investment**: Plans to increase investment in supply chain and infrastructure to strengthen sales, marketing, clinical support, and customer service [2][7] Future Projections - **Case Projections for 2025**: Expected total cases to reach between 490,000 and 500,000, with 250,000 in China and 240,000 to 250,000 internationally [3][10] - **Profitability Timeline**: The company aims for international operations to achieve monthly profitability by the first half of 2027 [3][11] Competitive Landscape - **Differentiation Strategy**: The company does not intend to engage in price wars but will focus on product and service differentiation [3][15] - **Response to Competition**: Plans to enhance clinical service teams and accelerate new customer onboarding in response to increasing competition [3][13] Challenges and Risks - **Increased Losses**: Anticipated significant expansion of international operating losses in the second half of the year due to delayed expenses, recruitment issues, and increased tariffs [3][17] - **Patent Litigation**: Facing patent lawsuits from Align Technology, which could impact operations, but the company is prepared with legal strategies [19] Market Dynamics - **Domestic Market Trends**: The domestic market has seen a decline in average prices, with a focus on maintaining market share through competitive pricing strategies [20] - **Collective Procurement Policies**: New collective procurement policies are being implemented, which may rationalize product prices and require the company to adapt [21] Strategic Partnerships - **Investment in Shuyaki**: The investment in Shuyaki aims to quickly penetrate emerging markets, leveraging complementary channels while maintaining independent operations [3][23] Global Supply Chain Development - **Supply Chain Resilience**: Building a more resilient global supply chain with production and design centers in key regions like Brazil and Southeast Asia [8][18] Macro Environment Impact - **Consumer Sentiment**: Global consumer willingness has decreased, affecting demand for non-essential medical services, including orthodontics [26] Additional Important Points - **Focus on Early Treatment**: Plans to enhance public awareness in early orthodontic treatment and strengthen professional service capabilities in lower-tier markets [2][7] - **Data Security and Compliance**: Emphasis on strengthening data security and compliance with international regulations [2][9]

Group 1 - The core issue is the continuous share reduction by the founder of Times Angel, Li Huamin, raising concerns about the company's future prospects [1] - Since its IPO, Li Huamin has reduced her shareholding from 14.26% to 6.37%, indicating a significant lack of confidence in the company's performance [1] - The company's market capitalization has plummeted approximately 88% from its peak of over 80 billion HKD to around 10 billion HKD [1] Group 2 - Times Angel has experienced a decline in net profit for three consecutive years, dropping from 286 million CNY in 2021 to only 10.02 million USD in 2024, indicating a systemic weakening of profitability [2] - The company's current price-to-earnings ratio stands at about 107 times, significantly higher than its competitor Align Technology's 34 times, suggesting that market expectations for future growth are not being met [2] - Despite substantial investments in overseas market expansion, Times Angel reported a loss of approximately 29.7 million USD in international markets for 2024, reflecting ongoing challenges in converting investments into profits [2] Group 3 - The global orthodontic industry is facing significant challenges, as evidenced by Align Technology's stock price drop of 30% due to poor Q2 performance and layoffs, indicating potential market saturation [2] - Times Angel's overseas revenue remains minimal, with high investment costs and long conversion cycles, posing risks amid intense international competition [2] - Industry experts suggest that without a rapid increase in sales to support its valuation, Times Angel may face escalating challenges in the near future [2]

Core Insights - The invisible orthodontic technology represents a significant breakthrough in modern orthodontics, providing a revolutionary innovation that enhances comfort, aesthetics, and convenience for consumers [1][18] - The market for invisible aligners is expected to grow significantly, with the industry projected to reach approximately 5.41 billion yuan in 2024, driven by increasing consumer demand for oral health and aesthetics [1][18] Industry Overview - Invisible aligners are a type of dental device used to correct misaligned teeth and bite issues, categorized into fixed, removable, invisible, functional, and lingual types [2] - The main types of orthodontic devices currently in the market include metal brackets, ceramic brackets, lingual brackets, and clear aligners, with clear aligners gaining popularity due to their aesthetic appeal and comfort [4][5] Industry Development History - The invisible aligner industry in China has evolved through two phases: initial development from 2001 to 2012 and rapid growth from 2013 to the present, marked by technological advancements and increased market awareness [7] - The approval of the first invisible aligner patent in China in 2006 and the establishment of the first production line in 2007 were pivotal moments that spurred market entry by numerous dental enterprises [7] Market Background - The per capita disposable income of Chinese residents has been steadily increasing, leading to a rise in healthcare spending, which has positively impacted the orthodontic market [9] - Per capita healthcare spending in China increased from 1,165 yuan in 2015 to 2,115 yuan in 2021, with a projected increase to 2,547 yuan in 2024, reflecting a growing focus on oral health [9] Industry Value Chain - The upstream of the invisible aligner industry includes raw materials and equipment, while the midstream involves production and manufacturing, and the downstream focuses on sales channels such as private clinics and dental hospitals [11] Current Industry Status - The orthodontic market in China has shown strong growth, expanding from 21.18 billion yuan in 2015 to an estimated 95.43 billion yuan in 2024, with a compound annual growth rate of 18.21% [15] - The invisible orthodontic market specifically has grown from 1.25 billion yuan in 2015 to 10.5 billion yuan in 2024, with a compound annual growth rate of 26.73% [15] Competitive Landscape - The Chinese invisible aligner market is characterized by a "dual oligopoly" structure, with companies like Times Angel and Invisalign dominating the market, while local brands are rapidly catching up [20] - Key players in the industry include Times Angel, which holds a 70% market share in China, and other emerging brands like Zhengya and Meilike that are focusing on mid-range markets [21][22] Future Trends - The industry is expected to see accelerated technological upgrades and the integration of artificial intelligence and 3D printing, enhancing treatment precision and production efficiency [26] - Market penetration is anticipated to extend from first and second-tier cities to lower-tier markets, with local brands leveraging cost advantages to capture market share [28] - Regulatory policies are expected to evolve, promoting standardization and integration within the industry, while insurance coverage for orthodontic services may enhance accessibility [29]